Key statistics
As of last trade Clearmind Medicine Inc (CWY0:DUS) traded at 1.06, 6.03% above its 52-week low of 0.995, set on Aug 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.06 |
---|---|
High | 1.06 |
Low | 1.06 |
Bid | 1.09 |
Offer | 1.16 |
Previous close | 1.05 |
Average volume | 0.00 |
---|---|
Shares outstanding | 4.06m |
Free float | 4.06m |
P/E (TTM) | -- |
Market cap | 4.91m USD |
EPS (TTM) | -12.73 USD |
Data delayed at least 15 minutes, as of Sep 24 2024 07:13 BST.
More ▼
Announcements
- Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
- Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
- Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
- Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
- Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
- Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
- Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug
- Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research
- Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
- Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
More ▼